NeoGenomics, Inc. Debt Securities, Available-for-sale, Amortized Cost, Current
NeoGenomics, Inc. (NEO) had Debt Securities, Available-for-sale, Amortized Cost, Current of $178.81 million as of 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Notes
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent · last filed 2022-05-09
- 2022-03-31: Debt Securities, Available-for-sale, Amortized Cost, Current $178.81M.
- 2021-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $199.46M.
- 2021-09-30: Debt Securities, Available-for-sale, Amortized Cost, Current $202.59M.
- 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost, Current $203.33M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Current |
|---|---|
| 2022-03-31 | $178.81M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $199.46M 10-Q · filed 2022-05-09 |
| 2021-09-30 | $202.59M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $203.33M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $190.91M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $67.59M 10-K · filed 2022-02-25 |
| 2020-09-30 | $50.40M 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |